<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02564588</url>
  </required_header>
  <id_info>
    <org_study_id>SEP360-221</org_study_id>
    <nct_id>NCT02564588</nct_id>
  </id_info>
  <brief_title>Dasotraline Binge Eating Disorder Study</brief_title>
  <official_title>A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunovion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the efficacy of flexibly-dosed dasotraline compared with placebo in adults with&#xD;
      moderate to severe Binge Eating Disorder (BED)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double blind, parallel group, multicenter, outpatient study evaluating&#xD;
      the efficacy and safety of flexibly-dosed dasotraline in adults with BED using dasotraline&#xD;
      (4, 6, and 8 mg/day) versus placebo over a 12 week treatment period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in number of binge days (defined as days during which at least 1 binge episode occurs) per week to Week 12</measure>
    <time_frame>12 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in number of binge episodes per week to Weeks 1, 2, 3, 4, 6, 8, 10, and 12</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects with a 4-week cessation from binge eating (defined as a 100% reduction for at least 28 consecutive days in the number of binge eating episodes prior to the EOT visit)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Clinical Global Impression-Severity (CGI S) score at Weeks 2, 4, 6, 8, 10, and 12</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Eating Disorder Examination Questionnaire Brief Version (EDE Q7) global score and 3 subscale scores (dietary restraint, shape/weight overvaluation, and body dissatisfaction) at Weeks 4, 8, and 12</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (Y BOCS BE) total score and subscale scores (obsessions and compulsions) at Weeks 2, 4, 6, 8, 10, and 12</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Sheehan disability Scale (SDS) total score and subscale scores (school/work disability, social life disability, and family life disability at Week 12</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) total score at Week 12</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Hamilton Anxiety Rating Scale (HAM A) score at Week 12</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Medical Outcomes Study 12 Item Short Form (SF 12) two component scores (physical component, mental health component) at Week 12</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of binge-eating responders who have ≥ 75% reduction in the number of binge eating episodes from Baseline at Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of binge-eating responders who have ≥ 50% reduction in the number of binge eating episodes from Baseline at Week 12</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of overall AEs, serious AEs (SAEs), and AEs (or SAEs) leading to discontinuations</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical laboratory evaluations (serum chemistry, hematology, and urinalysis)</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical evaluations (vital signs, orthostatic effects, and 12 lead ECGs)</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of suicidal ideation and suicidal behavior as assessed by the Columbia-suicide severity rating scale (C SSRS)</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change and percent change from baseline in body weight at Weeks 1, 2, 3, 4, 6, 8, 10, and 12</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change and percent change from baseline in BMI at Weeks 1, 2, 3, 4, 6, 8, 10, and 12</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in a fasting lipid panel (triglycerides, total cholesterol, high-density lipoprotein [HDL] cholesterol, and low-density lipoprotein [LDL] cholesterol) at Weeks 6 and 12</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in hemoglobin A1c level at Weeks 6 and 12</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting glucose level at Weeks 6 and 12</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the symptoms of withdrawal from Week 12/end of treatment (EOT) as measured by: - CSSA scores at Weeks 13, 14, and 15 - DESS scores at Weeks 13, 14, and 15 - HAM A scores at Weeks 13, 14, and 15 - MADRS scores at Weeks 13, 14, and 15.</measure>
    <time_frame>3 Weeks</time_frame>
    <description>The change in symptoms of withdrawal is a time frame of 3 weeks after treatment ends (weeks 13, 14, 15)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">319</enrollment>
  <condition>Binge Eating Disorder</condition>
  <arm_group>
    <arm_group_label>Dasotraline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dasotraline 4, 6, 8 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasotraline</intervention_name>
    <description>Dasotraline 4, 6, 8mg flexibly dosed once daily</description>
    <arm_group_label>Dasotraline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subject between 18 and 55 years of age, inclusive, at time of informed&#xD;
             consent.&#xD;
&#xD;
          -  Subject meets the following DSM 5 criteria for a diagnosis of BED. An episode of binge&#xD;
             eating is characterized by both:&#xD;
&#xD;
          -  Eating an amount of food larger than what most people would eat, in a discrete period&#xD;
             of time (eg, 2 hours)&#xD;
&#xD;
          -  Sense of lack of control over eating episode&#xD;
&#xD;
          -  Binge-eating episodes are associated with ≥ 3 of the following:&#xD;
&#xD;
          -  Eating much more rapidly than normal&#xD;
&#xD;
          -  Eating until uncomfortably full&#xD;
&#xD;
          -  Eating large amounts when not feeling hungry&#xD;
&#xD;
          -  Eating alone because of embarrassment&#xD;
&#xD;
          -  Feeling disgusted with oneself, guilty afterward&#xD;
&#xD;
          -  Binge-eating episodes are also associated with marked distress regarding the episode&#xD;
             and not associated with recurrent use of compensatory behavior (eg, bulimia nervosa).&#xD;
&#xD;
          -  Diagnosis is confirmed based on the eating-disorders module of the SCID, clinician&#xD;
             review of subject diaries, and the EDE Q.&#xD;
&#xD;
          -  Subject has a BED diagnosis including at least 2 binge eating days a week for at least&#xD;
             6 months prior to screening.&#xD;
&#xD;
          -  Subject's BED is of at least moderate severity.&#xD;
&#xD;
          -  Subject has a negative breath alcohol test and a negative urine drug screen (UDS) for&#xD;
             any illicit drug.&#xD;
&#xD;
          -  Female subject must have a negative serum pregnancy test at screening; females who are&#xD;
             post-menopausal (defined as at least 12 months of spontaneous amenorrhea) and those&#xD;
             who have undergone hysterectomy or bilateral oophorectomy will be exempted from the&#xD;
             pregnancy test.&#xD;
&#xD;
          -  Female subject of childbearing potential and male subject with female partner of&#xD;
             childbearing potential must agree to use an effective and medically acceptable form of&#xD;
             birth control throughout the study period. Note: Continued use of an effective and&#xD;
             medically acceptable form of birth control is recommended for 30 days after study&#xD;
             completion.&#xD;
&#xD;
          -  Subject must be able to comply with study drug administration and adhere to protocol&#xD;
             requirements.&#xD;
&#xD;
        Subject can read well enough to understand the informed consent form and other subject&#xD;
        materials.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has body weight index (BMI) of 18 kg/m2or less or greater than 45 kg/m2.&#xD;
&#xD;
          -  Subject has a lifetime history or current symptoms of bulimia nervosa or anorexia&#xD;
             nervosa.&#xD;
&#xD;
          -  Subject has started psychotherapy (eg, supportive psychotherapy, cognitive behavior&#xD;
             therapy, interpersonal therapy) within 3 months prior to screening. Note: Subjects&#xD;
             receiving stable ongoing psychotherapy for longer than 3 months are permitted to&#xD;
             enroll.&#xD;
&#xD;
          -  Subject is participating in a formal weight loss program (eg, Weight Watchers®) within&#xD;
             3 months prior to screening.&#xD;
&#xD;
          -  Subject has used a psychostimulant or mood stabilizer within the 3 months prior to&#xD;
             screening.&#xD;
&#xD;
          -  Subject has used any medications for the treatment of binge eating, other eating&#xD;
             disorders, obesity, or weight gain or any other medication that could result in weight&#xD;
             gain or weight loss including over-the-counter and herbal products within the 3 months&#xD;
             prior to screening.&#xD;
&#xD;
          -  Subject has a lifetime history of psychotic disorder, bipolar disorder, hypomania,&#xD;
             dementia, or ADHD as defined by the DSM 5 criteria.&#xD;
&#xD;
          -  Subject has a history of moderate to severe depression based on investigator's&#xD;
             judgment within the 6 months prior to screening or is currently taking or has taken&#xD;
             any medication for depression during the 3 months prior to screening.&#xD;
&#xD;
          -  Subject has a history of substance use disorder including alcohol use disorder&#xD;
             (excluding nicotine and caffeine) within the 12 months prior to screening, as defined&#xD;
             by the DSM 5 criteria.&#xD;
&#xD;
          -  Subject has MADRS score ≥ 18 at screening and Baseline visit.&#xD;
&#xD;
          -  Subject is considered a suicide risk or has any previous history of suicide attempt.&#xD;
&#xD;
          -  Subject answers &quot;yes&quot; to &quot;suicidal ideation&quot; item 4 (active suicidal ideation with&#xD;
             some intent to act, without specific plan) or item 5 (active suicidal ideation with&#xD;
             specific plan and intent) on the C SSRS assessment at screening (in the past month).&#xD;
             Subjects who answer &quot;yes&quot; to this question must be referred to the Investigator for&#xD;
             follow up evaluation.&#xD;
&#xD;
          -  Subject has type I diabetes mellitus or insulin-dependent diabetes mellitus.&#xD;
&#xD;
          -  Subject with type II diabetes mellitus has hemoglobin A1c ≥ 6.5% at screening, or has&#xD;
             initiated treatment with or changed the dose of a glucose-lowering agent within 3&#xD;
             months prior to screening.&#xD;
&#xD;
          -  Subject has known history of symptomatic cardiovascular disease, advanced&#xD;
             arteriosclerosis, structural cardiac abnormality, cardiomyopathy, documented heart&#xD;
             rhythm abnormalities, coronary artery disease, or other serious cardiac problems.&#xD;
&#xD;
          -  Subject has initiated treatment with or changed the dose of a lipid-lowering&#xD;
             medication within the 3 months prior to screening.&#xD;
&#xD;
          -  Subject has a history of moderate or severe hypertension that in the investigator's&#xD;
             opinion has not been medically stable or has required a change in dosage and/or&#xD;
             medication during the 3 months prior to screening.&#xD;
&#xD;
          -  Subject has a history of epilepsy, seizures (except childhood febrile seizures),&#xD;
             unexplained syncope or other unexplained blackouts (except single incident), or head&#xD;
             trauma with loss of consciousness lasting more than 5 minutes, or a history of&#xD;
             clinically significant repeated head-traumas without loss of consciousness.&#xD;
&#xD;
          -  Subject is female and pregnant or nursing.&#xD;
&#xD;
          -  Subject has had bariatric surgery, lap bands, duodenal stents, or other procedures for&#xD;
             weight loss.&#xD;
&#xD;
          -  Subject has a history of positive test for Hepatitis B surface antigen or Hepatitis C&#xD;
             antibody with liver function test results at screening above the upper limit of normal&#xD;
             (ULN) for the reference laboratory.&#xD;
&#xD;
          -  Subject without a history of positive test for Hepatitis B surface antigen or&#xD;
             Hepatitis C antibody has alanine aminotransferase (ALT) or aspartate aminotransferase&#xD;
             (AST) value ≥ 2 times the ULN at screening.&#xD;
&#xD;
          -  Subject has a blood urea nitrogen (BUN) value ≥ 1.5 times the ULN for the reference&#xD;
             range, fasting blood glucose ≥ 126 mg/dL (7.0 mmol/L), or hemoglobin A1c ≥ 6.5% at&#xD;
             screening.&#xD;
&#xD;
          -  Subject is known to have tested positive for human immunodeficiency virus (HIV).&#xD;
&#xD;
          -  Subject has a clinically significant abnormality on screening evaluation including&#xD;
             physical examination, vital signs, ECG, or laboratory tests that the investigator&#xD;
             considers to be inappropriate to allow participation in the study.&#xD;
&#xD;
          -  The subject's screening ECG shows a corrected QT interval using Fridericia's formula&#xD;
             (QTcF) of ≥ 450 msec for male subjects or ≥ 470 msec for female subjects. Eligibility&#xD;
             will be based on the core laboratory ECG interpretation report.&#xD;
&#xD;
          -  Subject has any life-time history of abuse or diversion of stimulants.&#xD;
&#xD;
          -  Subject has a history of allergic reaction or has a known or suspected sensitivity to&#xD;
             any substance that is contained in the study drug formulation.&#xD;
&#xD;
          -  Subject has enrolled in any Phase 2 or 3 trial of psychostimulants including&#xD;
             lisdexamfetamine dimesylate (Vyvanse®) for binge-eating disorder.&#xD;
&#xD;
          -  Subject is currently participating or has participated in any clinical trial within&#xD;
             the last 90 days or has participated in more than 2 clinical trials within the past&#xD;
             year. This includes studies using marketed compounds or devices.&#xD;
&#xD;
          -  Subject has previously been enrolled in a clinical trial of dasotraline (SEP 225289).&#xD;
&#xD;
          -  Subject is an investigational site staff member or the relative of an investigational&#xD;
             site staff member.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dasotraline Medical Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sunovioin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southern California Research</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwestern Research, Inc.</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmacology Research Institute</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Collaborative NeuroScience Network Inc.</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmacology Research Institute</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PCSD- Feighner Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Across America</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lytle and Weiss, PLLC</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Segal Institute for Clinical Research</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Advanced Medical Research</name>
      <address>
        <city>Alpharetta</city>
        <state>Georgia</state>
        <zip>30005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurotrials Research, INC.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capstone Clinical Research</name>
      <address>
        <city>Libertyville</city>
        <state>Illinois</state>
        <zip>60048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Goldpoint Clinical Research, Inc.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cypress Medical Research Center, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McLean Hospital</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adams Clinical Trials, LLC</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <zip>02472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Charles Psychiatric Associates - Midwest Research Group</name>
      <address>
        <city>Saint Charles</city>
        <state>Missouri</state>
        <zip>63304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princeton Medical Institute, LCC</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bioscience Research, LLC</name>
      <address>
        <city>Mount Kisco</city>
        <state>New York</state>
        <zip>10549</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Patient Priority Clinical Sites</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Clinical Research Center</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lindner Center Of Hope</name>
      <address>
        <city>Mason</city>
        <state>Ohio</state>
        <zip>45040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Star Medical Research, LLC</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IPS Research Company</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunstone Medical Research, LLC</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Center for Clinical Investigatons, INC.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Center for Clinical Investigatons, INC.</name>
      <address>
        <city>Salem</city>
        <state>Oregon</state>
        <zip>97301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lehigh Center For Clinical Research</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furturesearch Trials of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Center for Drug Development, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatric Medical Associates</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Research Institute</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuropsychiatric Associates</name>
      <address>
        <city>Woodstock</city>
        <state>Vermont</state>
        <zip>05091</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NeuroScience, Inc.</name>
      <address>
        <city>Herndon</city>
        <state>Virginia</state>
        <zip>20170</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Research Network (Seattle) LLC</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>September 29, 2015</study_first_submitted>
  <study_first_submitted_qc>September 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2015</study_first_posted>
  <disposition_first_submitted>September 20, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>September 20, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 28, 2017</disposition_first_posted>
  <last_update_submitted>September 20, 2017</last_update_submitted>
  <last_update_submitted_qc>September 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bulimia</mesh_term>
    <mesh_term>Feeding and Eating Disorders</mesh_term>
    <mesh_term>Binge-Eating Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

